Log in to post a reply
Dec 14, 2018 10:53PM
Dec 14, 2018 10:53PM
The two big companies are Foundation One and Caris. The National Cancer Institute (NCI) accepts their tests to get into trials there. It used to be that those were the only two they would accept. I don't know if that has changed. Both are excellent. Caris tests for a bit more things but also requires a very large sample size which can pose a problem in many cases. There are other players in the game now as well but I don't know about their reputability. I just had a CT guided liver biopsy today that is being sent to Foundation One so that I can get myself into an NCI trial for FGFR amplifications. I know that when I previously had a Foundation One test, they never charged me. They sent me a consent that permitted them to try to appeal directly with my insurance company which I signed and returned. After about year, my insurance company paid them and Foundation One never charged me the patient responsibility which was at least a few thousand, maybe more than that.
I also had a liquid biopsy last year, which my insurance paid for without dispute and the company never charged me the patient responsibility which was a few thousand. Interestingly, my first Foundation One report showed about 7 mutations or amplifications. The liquid biopsy showed none. I may have made the mistake of having the liquid biopsy when I was on treatment that was working. I suspect something would have showed up if I was progressing at the time.
Chart your own course. Dx at 30. Dx with mets at 38 while pregnant - extensive liver & bone involvement. Currently on Navelbine, Tamoxifen and XGeva. ER+/PR+, HER2 equivocal (IHC +2/FISH negative) as of most recent biopsy.
9/2006, IDC, Right, 1cm, Stage IIB, Grade 3, 1/16 nodes, ER+/PR+, HER2- (FISH)
9/22/2006 Mastectomy: Left, Right
11/6/2006 Adriamycin (doxorubicin), Cytoxan (cyclophosphamide), Taxotere (docetaxel)
3/15/2007 Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone)
12/2014, IDC, Stage IV, metastasized to bone/liver/other, Grade 3, ER+/PR-, HER2-
12/26/2014 Prophylactic ovary removal
12/26/2014 Aromasin (exemestane), Faslodex (fulvestrant)
6/18/2015 Ibrance (palbociclib)
3/10/2016 Xeloda (capecitabine)
5/14/2017 Aromasin (exemestane)
5/14/2017 Afinitor (everolimus)
8/18/2017 Abraxane (albumin-bound or nab-paclitaxel)
3/23/2018 Doxil (doxorubicin)
4/26/2019 Navelbine (vinorelbine)
4/26/2019 Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone)